Search clinical trials for: treated with exemestane and everolimus

Total 472557 results

Novartis Pharmaceuticals

Completed

An Open Label Study of Postmenopausal Women With Oestrogen Receptor Positive Locally Advanced or Metastatic Breast Cancer Treated With Everolimus (RAD001) With Exemestane, With Exploratory Epigenetic Marker Analysis (4EVERUK)

Oestrogen Receptor Positive Advanced Breast Cancer

United Kingdom
German Breast Group
Novartis

Terminated

Everolimus Beyond Progress for Patients Who Had Progress Under Everolimus and Exemestane (Evelyn)

Metastatic Breast Cancer

Germany
Pfizer

Recruiting

A Study to Learn About the Study Medicine Called PF-07220060 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment

Advanced or Metastatic Breast Cancer

United States, Israel, Taiwan, Argentina, Japan, Korea, Republic of, Canada, Australia, Brazil
University of Miami

Recruiting

Levels of Circulating Tumor DNA as a Predictive Marker for Early Switch in Treatment for Patients With Metastatic (Stage IV) Breast Cancer

Breast Cancer | Metastatic Breast Cancer | ER-positive Breast Cancer | HER2-negative Breast Cancer

United States
Hutchison Medipharma Limited

Recruiting

Efficacy and Safety of Fruquintinib in Combination With Sintilimab in Advanced Renal Cell Carcinoma (FRUSICA-2)

Advanced Renal Cell Carcinoma

China
Genentech, Inc.

Recruiting

A Study Evaluating the Efficacy and Safety of Giredestrant Plus Everolimus Compared With The Physician's Choice of Endocrine Therapy Plus Everolimus in Participants With Estrogen Receptor-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer (evERA Breast Cancer)

Estrogen Receptor (ER)-Positive, HER2-negative, Locally Advanced or Metastatic Breast Cancer

Korea, Republic of, United States, Spain, Taiwan, United Kingdom, Japan, Germany, Argentina, Turkey, Greece, Italy, Singapore, South Africa
Zealand University Hospital

Recruiting

The Effect of Salicylate on Platelet Function in CKD (Chronic Kidney Disease) Patients Treated With Aranesp (EPOASA)

Erythropoietin Adverse Reaction

Denmark
Eli Lilly and Company

Active, not recruiting

A Study of LY2835219 (Abemaciclib) in Combination With Therapies for Breast Cancer That Has Spread

Breast Neoplasms

United States
Pfizer

Active, not recruiting

Study to Compare Overall Survival in Medicare Patients With Metastatic Breast Cancer Treated With a Medicine Called Palbociclib in Combination With Aromatase Inhibitor and Aromatase Inhibitor by Itself.

Breast Cancer

United States
Veru Inc.

Terminated

Efficacy & Safety Evaluation of Enobosarm in Combo With Abemaciclib in Treatment of ER+HER2- Metastatic Breast Cancer (VERU-024)

Metastatic Breast Cancer

United States
Novartis Pharmaceuticals

Completed

A Study of Everolimus Plus Exemestane in Chinese Postmenopausal Women With Estrogen Receptor Positive, Locally Advanced, Recurrent, or Metastatic Breast Cancer After Recurrence or Progression on Non-steroidal Aromatase Inhibitor (BOLERO-5)

Advanced Breast Cancer

China
SWOG Cancer Research Network
National Cancer Institute (NCI)

Active, not recruiting

S1207 Hormone Therapy With or Without Everolimus in Treating Patients With Breast Cancer (e3)

Breast Cancer

United States, Puerto Rico
M.D. Anderson Cancer Center
Novartis; OSI Pharmaceuticals

Terminated

Erlotinib and RAD001 (Everolimus) in Patients With Previously Treated Advanced Pancreatic Cancer

Pancreatic Cancer

United States
Foundation of Cardiovascular Research and Education...
Abbott Medical Devices

Active, not recruiting

Complex All-comers and Patients With Diabetes or Prediabetes, Treated With Xience Sierra Everolimus-eluting Stents

Myocardial Infarction | Coronary Artery Disease | Angina Pectoris | Acute Coronary Syndrome | Angina, Unstable | Coronary Stenosis | Coronary Restenosis

Netherlands
Bayer

Completed

Study of Radium-223 Dichloride in Combination With Exemestane and Everolimus Versus Placebo in Combination With Exemestane and Everolimus in Subjects With Bone Predominant HER2 Negative Hormone Receptor Positive Metastatic Breast Cancer

Breast Neoplasms

Belgium, Spain, Hong Kong, Taiwan, Japan, United States, Austria, Singapore, Israel, United Kingdom, Italy, Korea, Republic of, France, Poland, Switzerland, Germany, Norway
ECOG-ACRIN Cancer Research Group
National Cancer Institute (NCI)

Terminated

Everolimus in Patients With Pancreatic Neuroendocrine Tumors Metastatic to the Liver Previously Treated With Surgery

Liver Metastases | Gastrinoma | Glucagonoma | Insulinoma | Pancreatic Polypeptide Tumor | Recurrent Islet Cell Carcinoma | Somatostatinoma

United States
Boehringer Ingelheim

Completed

The XENERA™ 1 Study Tests Xentuzumab in Combination With Everolimus and Exemestane in Women With Hormone Receptor Positive and HER2-negative Breast Cancer That Has Spread

Breast Neoplasms

Spain, United States, Belgium, Italy, Germany, France, Greece, United Kingdom, Portugal, Australia, Canada
ETOP IBCSG Partners Foundation
National Cancer Institute (NCI); Breast International Group

Active, not recruiting

Study of Bone Mineral Density in Women With Breast Cancer Treated With Triptorelin and Tamoxifen or Exemestane on Protocol IBCSG 25-02 (TEXT-Bone)

Breast Cancer | Osteoporosis

Belgium, Australia, Switzerland
Novartis Pharmaceuticals

Completed

Open-label, Phase II, Study of Everolimus Plus Letrozole in Postmenopausal Women With ER+, HER2- Metastatic or Locally Advanced Breast Cancer (BOLERO-4)

Hormone Receptor Positive Breast Cancer

United States, Argentina, Thailand, Japan, France, Korea, Republic of, Spain, Turkey, Hungary, United Kingdom, Portugal, Brazil, Netherlands
Pfizer

Completed

Study Of The Impact Of Inlyta In 2nd Line On The Treatment Outcomes Of mRCC Patients Treated With Sutent In 1st Line In The Real Life Setting (ADONIS)

Metastatic Renal Cell Carcinoma (mRCC)

Spain, Italy, Belgium, France, United Kingdom, Austria, Greece, Netherlands
Fox Chase Cancer Center

Withdrawn

Everolimus, Erlotinib Hydrochloride, and Radiation Therapy in Treating Patients With Recurrent Head and Neck Cancer Previously Treated With Radiation Therapy

Tongue Cancer | Recurrent Metastatic Squamous Neck Cancer With Occult Primary | Recurrent Salivary Gland Cancer | Recurrent Squamous Cell Carcinoma of the Hypopharynx | Recurrent Squamous Cell Carcinoma of the Larynx | Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity | Recurrent Squamous... and other conditions

United States
Novartis Pharmaceuticals

Completed

Treatment of Canadian Men and Pre/Peri/Post-menopausal Women With ER+ Advanced Breast Cancer in the Real-World Setting With Hormone Therapy ± Targeted Therapy (Treat ER+ight)

HR+ HER2- Men, Pre/Postmenopausal Advanced Breast Cancer

Canada
UNICANCER
Novartis; Fondation ARC

Completed

Molecular Alterations Associated With Resistance to Endocrine Therapy and Impacting Treatment With mTOR Inhibitor (SAFIR-TOR)

Metastatic Breast Cancer

France
Armando Santoro, MD

Completed

Study of Everolimus in Patients With Thymoma and Thymic Carcinoma Previously Treated With Chemotherapy (ONC-2010-001)

Thymoma and Thymic Carcinoma

Italy
Istituto Clinico Humanitas

Completed

Regulation of Lymphocyte Anti-tumor Response in Metastatic Patients Treated With the mTOR Inhibitor Everolimus

SOLID TUMOR

Italy
Dana-Farber Cancer Institute
Pfizer

Completed

Palbociclib With Everolimus + Exemestane In BC

Human Epidermal Growth Factor 2 Negative Carcinoma of Breast | Hormone Receptor (HR)-Positive Breast Cancer

United States
Palleos Healthcare GmbH
Pfizer; Cankado GmbH; WSG WOMEN´S HEALTHCARE STUDY GROUP; AGO-TraFo; AGO-B; Deutsche...

Terminated

Impact of eHealth-support on Quality of Life in Metastatic Breast Cancer Patients Treated With Palbociclib and Endocrine Therapy (PRECYCLE)

Breast Neoplasm

Germany
Novartis Pharmaceuticals

Completed

Study of Ribociclib With Everolimus + Exemestane in HR+ HER2- Locally Advanced/Metastatic Breast Cancer Post Progression on CDK 4/6 Inhibitor. (TRINITI-1)

Breast Cancer

United States
Novartis Pharmaceuticals

Completed

Phase Ib Trial of LEE011 With Everolimus (RAD001) and Exemestane in the Treatment of Hormone Receptor Positive HER2 Negative Advanced Breast Cancer

Breast Cancer

United States, Spain, Belgium, Hong Kong, France
Novartis Pharmaceuticals

Completed

A Phase II Study of Everolimus in Combination With Exemestane Versus Everolimus Alone Versus Capecitabine in Advance Breast Cancer. (BOLERO-6)

Breast Cancer

Belgium, Hungary, Spain, Argentina, Russian Federation, Sweden, Lebanon, Australia, Denmark, Ireland, United Kingdom, Thailand, Turkey, Peru, Brazil, Malaysia, India, United States
Centre Hospitalier Universitaire de Besancon

Unknown

Immune Response for Patients With Metastatic Breast Cancer Treated by Everolimus (EVERIMMUN)

Breast Cancer

France
Novartis Pharmaceuticals

Completed

Combination of RAD001 and Erlotinib in Patients With Advanced Non Small Cell Lung Cancer Previously Treated Only With Chemotherapy

Non Small Cell Lung Cancer

France, Canada, United States, Russian Federation, Denmark
Novartis Pharmaceuticals

Completed

Study of Safety and Efficacy of Alpelisib With Everolimus or Alpelisib With Everolimus and Exemestane in Advanced Breast Cancer Patients, Renal Cell Cancer and Pancreatic Tumors

Neoplasms | Kidney Neoplasms | Breast Neoplasms | Pancreatic Neuroendocine Neoplasms (pNETs)

France, Germany, United States, Netherlands, Italy, Spain, United Kingdom, Hong Kong, Hungary
Translational Oncology Research International
National Cancer Institute (NCI); University of California, Los Angeles

Completed

Everolimus in Treating Patients With Previously Treated Unresectable or Metastatic Esophageal Cancer or Stomach Cancer

Gastric Cancer | Esophageal Cancer

United States
Abramson Cancer Center of the University of Pennsylvania
University of Pittsburgh; Rutgers Cancer Institute of New Jersey

Completed

Autophagy Inhibition to Augment Mammilian Target of Rapamycin (mTOR) Inhibition: A Phase I/II Trial of RAD001 and Hydroxychloroquine (HCQ) in Patients With Previously Treated Renal Cell Carcinoma

Metastatic Clear Cell Renal Cell Carcinoma

United States
Novartis Pharmaceuticals

Completed

Study in Post-menopausal Women With Hormone Receptor Positive, HER2-negative Advanced Breast Cancer (EVEREXES)

Post Menopausal Breast Cancer

Taiwan, Malaysia, Turkey, Australia, Korea, Republic of, Thailand, Jordan, India, Vietnam, Morocco, Tunisia, Indonesia, South Africa
SCRI Development Innovations, LLC
Novartis

Completed

Everolimus Combined With Anti-estrogen Therapy in Hormone-Receptor-Positive HER-2 Negative Advanced Breast Cancer

Breast Cancer

United States
University of Arizona
National Cancer Institute (NCI)

Terminated

Everolimus in Restoring Salivary Gland Function in Participants With Locally Advanced Head and Neck Cancer Treated With Radiation Therapy

Head and Neck Cancer | Xerostomia | Salivary Gland Dysfunction

United States
Comprehensive Support Project for Oncology Research
Novartis Pharmaceuticals

Completed

Evaluation of Oral Care to Prevent Oral Mucositis in ER Positive MBC Patients Treated With Everolimus: Phase 3 RCT

Breast Cancer

Japan
Amsterdam UMC, location VUmc
Novartis; Borstkanker Onderzoek Groep

Unknown

Analysis of Tumor Tissue and Circulating Genetic Material in the Blood to Obtain Further Insight in the Effectiveness of Everolimus When Combined With Exemestane

Metastatic Breast Cancer | Hormone Receptor Positive Malignant Neoplasm of Breast

Netherlands
Case Comprehensive Cancer Center
National Cancer Institute (NCI)

Terminated

RAD001(Everolimus) in Treating Patients With Myelodysplastic Syndromes

Myelodysplastic Syndromes

United States
University Hospital, Bordeaux
Novartis

Completed

Proportion of CMV Seropositive Kidney Transplant Recipients Who Will Develop a CMV Infection When Treated With an Immunosuppressive Regimen Including Everolimus and Reduced Dose of Cyclosporine Versus an Immunosuppressive Regimen With Mycophenolic Acid and Standard Dose of Cyclosporine A (EVERCMV)

Transplantation Infection | Cytomegalovirus Infection

France
European Institute of Oncology

Completed

A Biological Prospective Study in Patients With Metastatic Pancreatic NETs Treated With Everolimus

Pancreatic Neuroendocrine Tumour Metastatic

Italy
Institut d'Investigació Biomèdica de Bellvitge
Fundació La Marató de TV3

Completed

Comparison of the Vasomotor Function and Myocardial Flow in Patients Treated With Bioresorbable and Metallic Stents at 1 Year (BVS-Flow)

Stable Angina

Spain
Mario Negri Institute for Pharmacological Research

Terminated

Outcome-related Factors in Patients With Metastatic Renal Cell Carcinoma Treated With Everolimus (ORCHIDEE) (ORCHIDEE)

Renal Cell Carcinoma

Italy
iOMEDICO AG
Novartis

Completed

Open Label, Single Arm Trial to Characterize Patients With Metastatic RCC Treated With Everolimus After Failure of the First VEGF-targeted Therapy (MARC-2) (MARC-2)

Metastatic Renal Cell Carcinoma | Failure of Exactly One Prior VEGF-targeted Therapy

Germany
iOMEDICO AG
Novartis Pharmaceuticals; Arbeitsgemeinschaft fur Internistische Onkologie

Completed

Patient Preference for Everolimus in Combination With Exemestane or Capecitabine in Combination With Bevacizumab (IMPROVE)

Breast Cancer Recurrent | HER2/Neu-negative Carcinoma of Breast | Hormone Receptor Positive Malignant Neoplasm of Breast

Germany
Novartis Pharmaceuticals

Completed

Efficacy, Safety and Tolerability of Everolimus in Combination With Reduced Exposure Cyclosporine or Tacrolimus in Paediatric Liver Transplant Recipients.

Renal Function | Liver Transplant

United States, Germany, Spain, Belgium, France, Hungary, Australia, Sweden, Italy, Canada, United Kingdom, Denmark
UNC Lineberger Comprehensive Cancer Center
National Cancer Institute (NCI)

Completed

Everolimus, Fluorouracil, Leucovorin, Panitumumab, and Oxaliplatin in Treating Patients With Tumors That Did Not Respond to Treatment

Unspecified Adult Solid Tumor, Protocol Specific

United States
Novartis Pharmaceuticals

Completed

Everolimus in Combination With Exemestane in the Treatment of Postmenopausal Women With Estrogen Receptor Positive Locally Advanced or Metastatic Breast Cancer Who Are Refractory to Letrozole or Anastrozole (BOLERO-2)

Breast Cancer

United States, Belgium, Canada, France, Spain, Turkey, Japan, Egypt, Germany, Austria, Poland, Sweden, United Kingdom, Thailand, Hungary, Australia, Italy, Netherlands, Brazil, Hong Kong, Czech Republic, Korea, Republic of, New Zealand and more

Search clinical trials for: treated with exemestane and everolimus

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Panama

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations